Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 9/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489002 | 0.87 | HPGD (0.39) | HPGDMEN1KMT2AL3MBTL1NPSR1 | |
| SCHEMBL6497506 | 0.87 | PDE3B (0.43) | ALOX5APHPGDMEN1KMT2AL3MBTL1 | |
| SCHEMBL6490952 | 0.84 | ALOX5AP (0.43) | ALOX5APMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL6487079 | 0.81 | PPARG (0.48) | ALOX5APMEN1KMT2ANPSR1MAOB | |
| SCHEMBL6497616 | 0.79 | PPARG (0.47) | ALOX5AP | |
| SCHEMBL6488591 | 0.77 | ALOX5AP (0.44) | ALOX5AP | |
| SCHEMBL6487805 | 0.77 | KDM4E (0.42) | MEN1KMT2AL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL6499428 | 0.76 | SYK (0.42) | ALOX5APHPGDMEN1KMT2AL3MBTL1 | |
| SCHEMBL6490693 | 0.76 | MRGPRX4 (0.43) | ALOX5APHPGDNPSR1ALDH1A1 | |
| SCHEMBL6920280 | 0.76 | PDE3B (0.42) | ALOX5APMEN1KMT2ANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | ALOX5AP 4663/4885HPGD 2381/4885MEN1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.